Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

Coleman, 2013, Latest research and treatment of advanced-stage epithelial ovarian cancer, Nat Rev Clin Oncol, 10, 211, 10.1038/nrclinonc.2013.5

2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166

Burger, 2007, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study, J Clin Oncol, 25, 5165, 10.1200/JCO.2007.11.5345

Cannistra, 2007, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer, J Clin Oncol, 25, 5180, 10.1200/JCO.2007.12.0782

Kaye, 2007, Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?, J Clin Oncol, 25, 5150, 10.1200/JCO.2007.13.6150

Du Bois, 2013, AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer [abstract], Int J Gyn Cancer, 23, PL01

Burger, 2011, Incorporation of bevacizumab in the primary treatment of ovarian cancer, N Engl J Med, 365, 2473, 10.1056/NEJMoa1104390

Perren, 2011, A phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med, 365, 2484, 10.1056/NEJMoa1103799

Du Bois, 2013, Proc Am Soc J Clin Oncol, 31

Stockler, 2014, Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer, J Clin Oncol, 32, 1309, 10.1200/JCO.2013.51.4240

Aghajanian, 2012, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, J Clin Oncol, 30, 2039, 10.1200/JCO.2012.42.0505

Ledermann, 2013, Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial, Eur J Cancer, 49

Coxon, 2010, Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody, Mol Cancer Ther, 9, 2641, 10.1158/1535-7163.MCT-10-0213

Herbst, 2009, Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors, J Clin Oncol, 27, 3557, 10.1200/JCO.2008.19.6683

Karlan, 2012, Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer, J Clin Oncol, 30, 362, 10.1200/JCO.2010.34.3178

Monk, 2013, Incidence and management of edema associated with trebananib (AMG 386), Gynecol Oncol, 130, 636, 10.1016/j.ygyno.2013.05.023

Baird, 2010, Weekly paclitaxel in the treatment of recurrent ovarian cancer, Nat Rev Clin Oncol, 7, 575, 10.1038/nrclinonc.2010.120

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Basen-Engquist, 2001, Reliability and validity of the functional assessment of cancer therapy-ovarian, J Clin Oncol, 19, 1809, 10.1200/JCO.2001.19.6.1809

Rustin, 2011, Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), Int J Gynecol Cancer, 21, 419, 10.1097/IGC.0b013e3182070f17

Collett, 2003

Lin, 1993, Checking the Cox model with cumulative sums of Martingale-based residuals, Biometrika, 80, 557, 10.1093/biomet/80.3.557

Herzog, 2014, Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper, Gynecol Oncol, 132, 8, 10.1016/j.ygyno.2013.11.008

Pfisterer, 2006, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J Clin Oncol, 24, 4699, 10.1200/JCO.2006.06.0913

Monk, 2010, Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer, J Clin Oncol, 28, 3107, 10.1200/JCO.2009.25.4037

Broglio, 2009, Detecting an overall survival benefit that is derived from progression-free survival, J Natl Cancer Inst, 101, 1642, 10.1093/jnci/djp369

Eskens, 2006, The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review, Eur J Cancer, 42, 3127, 10.1016/j.ejca.2006.09.015

Colombo, 2013, Optimizing treatment of the partially platinum-sensitive ovarian cancer patient, Future Oncol, 9, 19, 10.2217/fon.13.206

Peeters, 2013, A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma, Br J Cancer, 108, 503, 10.1038/bjc.2012.594

Eatock, 2011, Randomized, double-blind, placebo-controlled phase II study of AMG 386 in combination with cisplatin and capecitabine (CX) in patients (pts) with metastatic gastroesophageal adenocarcinoma, Proc Am Soc Clin Oncol, 29

Armstrong, 2002, Relapsed ovarian cancer: challenges and management strategies for a chronic disease, Oncologist, 7, 20, 10.1634/theoncologist.7-suppl_5-20